Evercore ISI has updated its outlook on CVS Health (NYSE:CVS) shares, raising the price target from $60.00 to $65.00 while maintaining an Outperform rating. The adjustment comes in anticipation of future performance dynamics,

UnitedHealth reported fourth-quarter results on Thursday that reflected persistent challenges for the health insurance sector.

According to the Federal Trade Commission, UnitedHealth Group has been charging patients markups on lifesaving drugs. Between 2017 and 2022, UnitedHealth Group’s Optum, Cigna’s Express Scripts and CVS Health’s CVS Caremark marked up their prices by hundreds — and in some cases,

Witty's comments came during the company's first earnings call since the killing of Brian Thompson, the CEO of the company's insurance arm UnitedHealthcare.

UnitedHealth, the biggest insurance company in America, is receiving backlash after an FTC report revealed that it was overcharging cancer patients by 1000%.

UnitedHealth Group Inc. operates the nation’s largest ... Shares of other other health care conglomerates like CVS Health and Cigna also were down.

FTC stated that the 'Big 3' PBM organisations collectively generated over £5.94 billion ($7.3 billion) in revenue from 2017 to 2022.

Shares of UnitedHealth, the first company with a large health insurance component to report earnings, fell 4.7% in early trading, dragging down rivals along with it. CVS Health and Elevance Health ...

UnitedHealth Group CEO Says Complex US Healthcare System ... dragging down rivals along with it. CVS Health and Elevance Health were both down more than 2%. Medical costs in the fourth quarter ...

The FTC report found that from 2017 to 2022, three PBMs—UnitedHealth Group's Optum, CVS Health's CVS Caremark and Cigna's Express Scripts—marked up prices at their pharmacies by hundreds or thousands of percent.

The Baltimore City Board of School Commissioners is suing Eli Lilly and Co., UnitedHealth Group, CVS and several other drug manufacturers for allegedly colluding to inflate the cost of insulin to

Elevance Health's financial outlook for FY 2025 anticipates GAAP diluted earnings per share (EPS) to be in the range of $30.40 to $31.10 and adjusted diluted EPS to be in the range of $34.15 to $34.85. The company also announced a 5% increase in its quarterly dividend to $1.71 per share.